Georgia Tech Celebrates National Cancer Survivor Month gatech.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gatech.edu Daily Mail and Mail on Sunday newspapers.
High-intensity Focused Ultrasound (HIFU) therapy Market - Report Provide the Development Strategies Adopted by Key Industry
infinityMay 15, 2021
The global Adjuvant Breast Cancer Therapy Market study estimates revenue and volume growth at the global, regional, and country levels, as well as an overview of the most recent industry developments in each sub-segment from to 2027.
Infinity Business Insights has segmented the global Adjuvant Breast Cancer Therapy Market report for the purposes of this study based on product, use, end-use, type, and area. The Adjuvant Breast Cancer Therapy Market research report offers not only projections and predictions, but also a straightforward assessment of these figures in terms of market dynamics. These Adjuvant Breast Cancer Therapy market insights combine a data-driven analysis framework with qualitative workshops for business managers, CXOs, politicians, and investors.
Abstract
In this article, we demonstrate that specifically engineered oxide nanoparticles (NPs) have the potential to act as theranostic materials that are able to generate or prevent oxidative stress through their oxi-redox activity in various types of malignant and nonmalignant cells. The oxi-redox activity is related to the type and presence of surface defects, which is modified with appropriate synthesis conditions. In the present work, we used MDA-MB-231 and MCF-7 human breast cancer cells and nonmalignant MCF-10A human breast cells to demonstrate how controlled oxidative stress mediated by specifically nanoengineered indium tin oxide (ITO) NPs can selectively induce cell death in the cancer cells while reducing the oxidative stress in the normal cells and supporting their proliferation. The ITO NPs are also promising nanotheranostic materials for cancer therapy and contrast agents because of their multimodal imaging capabilities. We demonstrate that the synthesized ITO NPs can
Best Life: New drug treating triple negative breast cancer
Best Life: Treatment for tripe-negative breast cancer By Ivanhoe Broadcast News | March 16, 2021 at 7:57 AM CDT - Updated March 16 at 6:17 PM
PITTSBURGH, Pa. (Ivanhoe Newswire)â About 15 percent of all women diagnosed with breast cancer have triple-negative breast cancer, meaning drugs that target estrogen, progesterone, and HER-2 proteinâwonât work. In the past, if the cancer returned, patients have had very few options. More on a newly approved drug that is stopping the cancer in its tracks.
Jane Ellen Keenan is a cancer warrior, battling triple-negative breast cancer since 2013. She had six months of chemo, and surgery. The cancer was gone . for a time.